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APOE ε4 status is associated with white matter hyperintensities volume 
accumulation rate independent of AD diagnosis  
Abstract 
To assess the relationship between carriage of APOE ε4 allele and evolution of white 
matter hyperintensities (WMH) volume, we longitudinally studied 339 subjects from 
the ADNI cohort with diagnoses ranging from normal controls to probable 
Alzheimer’s disease (AD). A purpose-built longitudinal automatic method was used 
to segment WMH using constraints derived from an atlas-based model selection 
applied to a time-averaged image. Linear mixed models were used to evaluate the 
differences in rate of change across diagnosis and genetic groups. After adjustment 
for covariates (age, sex, and total intracranial volume), homozygous APOE ε4ε4 
subjects had a significantly higher rate of WMH accumulation (22.5 % per year 95% 
CI [14.4, 31.2] for a standardized population having typical values of covariates) 
compared with the heterozygous (ε4ε3) subjects (10.0 % per year [6.7, 13.4]) and 
homozygous ε3ε3 (6.6 % per year [4.1, 9.3]) subjects.  Rates of accumulation 
increased with diagnostic severity; controls accumulated 5.8% per year 95% CI[2.2, 
9.6] for the standardized population, early mild cognitive impairment (MCI) 6.6% 
per year [3.9, 9.4], late MCI 12.5% per year [8.2 17.0] and AD subjects 14.7% per 
year [6.0 24.0]. Following adjustment for APOE status these differences became non-
statistically significant suggesting that APOE ε4 genotype is the major driver of 
accumulation of WMH volume rather than diagnosis of AD.  
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Introduction 
 
The APOE gene, and specifically its ε4 allelic variant, has an important dose-
dependent association with Alzheimer’s disease (AD) risk (Verghese, Castellano, & 
Holtzman, 2011). APOE ε4 is associated with increased cerebral amyloid plaque 
deposition and amount of white matter hyperintensities (WMH). 
 
WMH are associated with increasing age in apparently healthy elderly subjects and 
inversely related to executive function and processing speed (Mortamais, Artero, & 
Ritchie, 2013). They are thought to be a marker of cerebral small vessel disease, and 
possible pathophysiological explanations for the imaging change include partial 
ischemia of the tissue and degradation of the blood brain barrier (Wardlaw, Valdés 
Hernández, & Muñoz-Maniega, 2015). In line with a possible vascular etiology, WMH 
are associated with cardiovascular risk factors such as hypertension (Abraham et al., 
2015), diabetes (Brundel, Kappelle, & Biessels, 2014) and smoking (Power et al., 
2015) . However, WMH also occur with greater frequency in AD patients (Holland et 
al., 2008; Provenzano et al., 2013) compared with normal controls. Interestingly, 
from the point of view of AD, parenchymal WMH can also be related to cerebral 
amyloid angiopathy (CAA), where amyloid protein affects blood vessel function, 
potentially impairing the supply of oxygen and nutrients to the brain (Esiri et al., 
2015; Greenberg, 2002; Holland et al., 2008; Zipfel, Han, Ford, & Lee, 2009). Studies 
that have investigated the link between WMH and APOE status have led to 
contradictory results (Benedictus et al., 2013; Brickman et al., 2014; Esiri et al., 
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2015; Kim et al., 2013). Many of those studies, however, were hampered by a cross-
sectional design. 
 
We studied the association between APOE ε4 status and WMH in a longitudinal 
framework, for a population with limited cardiovascular risk factors but 
heterogeneous in terms of AD diagnoses. We used a novel approach for automatic 
longitudinal WMH lesion segmentation, with the aim of providing greater precision 
to the assessment of WMH changes and thereby clarifying the relevance of APOE ε4 
in the accumulation of WMH. 
Methods 
Data selection 
Data used were obtained from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database (adni.loni.usc.edu). The ADNI project was launched in 2003 as a 
public-private partnership, whose primary goal has been to test whether serial 
magnetic resonance imaging (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessment can be combined 
to measure the progression of mild cognitive impairment (MCI) and early AD. 
Information about the study can be found at www.adni-info.org.  Data collection was 
approved by each centre’s Institutional Review Board and participants gave written 
informed consent at time of enrolment. 
At their initial visit, following clinical and neuropsychological assessment, each 
subject was given one of four diagnoses: normal control (NC), early mild cognitive 
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impairment (EMCI), late mild cognitive impairment (LMCI) or probable AD. To be 
included in the ADNI study, newly recruited participants had to score 4 or below on 
the modified Hachinski scale for cerebrovascular disease, thereby limiting the range 
of WMH at baseline. Furthermore, included MCI subjects had to present with an 
amnestic form of cognitive decline as opposed to a vascular form associated with 
executive dysfunction.   
  
We selected subjects from the ADNI database using criteria based on available 
quality scans. Only subjects for whom at least four imaging time points with 
adequate FLAIR images were selected. In order to avoid introducing any 
preprocessing bias into the analysis, only subjects with T1 scans preprocessed with 
N3 histogram sharpening, and corrected for B1 bias field and gradient non linearity 
were used. Subjects were further excluded if they had poor quality imaging. Figure 1 
presents the flowchart of data selection. According to the ADNI record of adverse 
events, none of the selected subjects suffered from stroke during the course of the 
study. 
 
The genotyping for APOE was performed at screening visit using DNA extracted by 
Cogenic using a 3mL aliquot of EDTA blood while the level of CSF Aβ is obtained 
using the xMAP Luminex platform and the Innogenetics/Fujirebio AlzBio3 
immunoassay kits. Further details on the diagnostic procedure, scanning  and 
imaging protocols as well as genotyping and Aβ measurement can be found at 
http://www.adni-info.org/scientists/ADNIStudyProcedures.aspx. 
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Image analysis 
We developed a novel fully automatic multimodal lesion segmentation pipeline to 
jointly analyze all longitudinal imaging time points together. Instead of considering 
each time point independently and thereby increasing the variability in the 
longitudinal assessment, an average image was iteratively created. Alignment was 
achieved through matching intensities of normal tissue in the images in an iterative 
procedure involving steps of affine and non-rigid registration using jointly the two 
pulse sequences, the FLAIR sequence being affinely aligned to the T1 weighted 
image (Modat et al., 2010, 2014). Based on the results of an existing method (Sudre 
et al., 2015) applied to the average image, the WMH segmentation at each time point 
was generated. In brief, this method builds a Bayesian probabilistic data model 
based on an evolving Gaussian mixture model (GMM) which is able to account for 
observation outliers and incorporates anatomical priors and contextual information 
for the average appearance model. The model was then further used to constrain the 
segmentation at each time point. To do so, the model structure (number of Gaussian 
components) and its associated parameters and resultant segmentation were used 
to initialize the optimization of the data modelling in the original space of each time 
point and provide a priori information. Probabilistic lesion maps were obtained from 
the GMM based on the evaluation of outlierness when compared to the healthy WM 
and integrated to determine the final WMH volumes. 
Figure 2 displays the flowchart of the longitudinal framework with its 3 main steps: 
average image building, probabilistic model selection and constraint over the 
individual time points. 
The total intracranial volume (TIV), that included total brain volume, ventricles and 
CSF between the brain and meninges, was automatically obtained using a previously 
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described method (Cardoso et al., 2015). A single measure of TIV for each individual, 
generated from the average image, was used as a covariate in statistical analyses. 
 
 Statistical analysis  
In order to assess how our method compared to the first measurements obtained 
through the method detailed by De Carli et al. (De Carli, Maillard, & Fletcher, 2013) 
(UC Davis’ method), made available on the ADNI database, we calculated Pearson’s 
and Spearman’s correlation coefficients. In addition, we assessed agreement 
between methods through construction of the geometric mean of the ratio of the 
volumes together with 95% reference ranges. Since differences in volumes may be 
related to lesion size we reported these ratios and corresponding reference ranges 
separately in low vs. high lesion volumes (bisected at the median of the mean of the 
two volumes). 
 
All the statistical analyses were performed using Stata 12 v1. Due to the skewness of 
the WMH volumes they were log-transformed prior to analysis. Cross-sectional 
analysis of the baseline log-transformed WMH volumes was performed using linear 
regression models including age, TIV and sex as covariates in all models. Four 
models were fitted: these included diagnosis status (Model ASTD), genetic status 
(Model ASTG), genetic and diagnosis status (Model ASTGD), and genetic status and 
CSF Aβ42 concentration (Model ASTGAβ) as predictor variables. F-tests were used 
to assess differences between groups after adjustment for covariates. Fitted group 
specific means, standardized to a 50/50 mixture of males and females at age 72.2 
years with a TIV of 1552 mL (with 95% confidence intervals), were also computed 
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and back-transformed.   These age and TIV values were chosen as they were the 
mean values across all subjects. 
 
Longitudinal changes in WMH volume were assessed using linear mixed models, 
with random intercepts and slopes, for the repeated measures. Linear mixed models, 
provided that they are properly specified, appropriately allow for the non-
independence of repeated measures from the same subject (Verbeke & Molenberghs, 
2000). The dependent variable in all models was the log-transformed volume of 
WMH with time from initial measurement treated as both a fixed and random effect 
(thereby allowing slopes to differ between subjects). Other fixed effects were group 
terms (diagnosis and/or APOE status) and group-time interaction terms (thereby 
allowing mean rates of change to differ between groups) and age, TIV, and sex and 
their interactions with time.  One model (Model ASTG) investigated differences in 
slope between the APOE groups, a second (Model ASTD) differences between the 
diagnostic groups and a third (Model ASTGD) differences according to both of these 
factors simultaneously. A fourth model (Model ASTGAβ) investigated APOE status 
and CSF Aβ42 concentration as predictors of rates of WMH volume progression. 
Wald tests were used to compare rates of change between groups after adjustment 
for covariates. Fitted group specific mean rates of change (and 95% confidence 
intervals), standardized to a 50/50 mixture of males and females aged 72.2 with a 
TIV of 1552mL, were computed and back-transformed from each model. 
 
Both cross-sectional and longitudinal analyses were also performed adding systolic 
blood pressure and diabetes status as additional covariates, treating these in the 
same way as age, sex and TIV in all models . However, since hypertension and 
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diabetes are associated with WMH volumes, and are likely on the causal pathway 
between APOE status and WMH levels, these results are presented in supplementary 
analyses. Finally, in order to understand whether length of follow-up influenced rate 
of WMH accumulation we added this variable as an additional covariate in all 
longitudinal models.  
Results 
Demographic results 
The inclusion criteria led to the selection of 339 subjects that collectively had 1620 
scans. The number of acquired time points per subject varied from 4 to 7 (mean 5.15 
SD 1.82) and the total length of time from baseline assessment varied from 11 to 52 
months (mean 24, SD 9.3). Table 1 shows the demographics of the study population 
by genetic status and diagnostic group. As expected, the AD subjects had lower CSF 
Aβ 42 concentrations than control subjects, with the MCI subjects having 
intermediate values (AD < LMCI < EMCI < NC). CSF Aβ 42 concentrations were lower 
in subjects with an APOE ε4 allele (44 < 42< 43 < 33).  Although age was comparable 
across APOE status, EMCI and LMCI were on average younger than NC and AD. 
Volumes using our method and the method from UC Davis at first available 
measurement were strongly associated (Pearson correlation = 0.9, Spearman = 
0.95). Absolute volume differences were apparent between methods with our 
method typically producing smaller values than UC Davis’ method. For low lesion 
volumes, the geometric mean of the ratio was 0.4 with a 95% reference range of 0.1 
to 1.2. Analogous results for high volumes (greater than the median) were 0.6 with a 
95% reference range of 0.3 to 1.1.  
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Cross-sectional associations of WMH 
The baseline data are summarized in Table 2. There was evidence (p = 0.016,   Model 
ASTD) that the volume of WMH differed between the diagnosis severity groups, the 
difference being driven mostly by the low volumes observed in NC compared with 
the three other groups. Although the mean WMH volume in the AD group was 
slightly lower than that in the EMCI and LMCI groups, these differences were not 
statistically significant and the 95% confidence interval for the AD group mean was 
wide, reflecting the fact that this group contains the fewest subjects. Similar results 
were seen when the differences between the diagnostic groups were adjusted for 
APOE status (p-value from joint test of differences = 0.033, Model ASTGD). 
Considering the Aβ42 level as a continuous marker also provided evidence of an 
association (p<0.0005) with WMH volume when adjusting for APOE  (Model 
ASTGAβ).  
Across APOE status, an increase in WMH volume with the number of ε4 alleles was 
observed, although this was not statistically significant when APOE was considered 
with or without adjustment for diagnostic group or Aβ. In all these models, the 
associations with age and TIV were significant (p<0.001) and the gender difference 
was significant for Model ASTG (p=0.013) such that females tended to have more 
WMH. There was no evidence that diabetes was related to WMH volume, but there 
was evidence of an association for systolic blood pressure with each 10 mmHg 
increase associated with a 12% (95% CI (4.8, 21.1) increase in volume. The inclusion 
of these factors as covariates however did not materially alter the pattern of results 
(see Supplemental Material).  
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Models of longitudinal WMH volume change. 
Table 3 summarizes the results for the longitudinal assessment of the WMH rate of 
change. Evolution rates are presented as  standardized mean values of percentage 
change in volume per year, with the standardized population being a 50:50 mix of 
males and females having the mean value of age and TIV across all participants..  
 
There was strong evidence (p=0.0002) that mean rates of change differed between 
the APOE groups with the largest mean rate in the APOE ε4ε4 group and the lowest 
in the APOE ε4ε2 group. The standardized mean rate in the APOE ε4ε4 group 
(22.5%/year CI [14.4, 31.2]) was significantly higher than in each of the other 
groups (10.0%/year [6.7, 13.4] in the ε4ε3 group and 6.6%/year [4.1 ,9.3] in the 
ε3ε3 group, 2.8%/year [-2.6 ,8.5] in the ε3ε2 group and -3.2%/year [-14.8 ,9.9] in 
the ε4ε2 group). The rates in the ε4ε3 and ε3ε3 groups did not differ significantly 
from each other. The progression in ε4ε2 group appeared lower than for the ε4ε3 
group, although this was not formally statistically significant (p=0.055). Due to the 
very small sample size, the CI for the ε4ε2 group was very large. Adjustment for 
either diagnostic group (Model ASTGD) or Aβ status (Model ASTGAβ) slightly 
attenuated the differences between the groups without altering the overall pattern. 
In the latter model the dependency of the rate of change on the CSF Aβ level was just 
formally statistically significant (p <0.041 for interaction with time). 
 
Rates of change also appeared to increase with diagnosis severity (AD > LMCI > 
EMCI > NC) (p=0.03, Model ASTD) ranging from a mean rate of 5.6%/year in the NC 
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to 14.8%/year for the AD.  This effect was no longer significant when adjusting 
additionally for APOE status (p=0.18). There was no evidence that diabetes or 
systolic blood pressure was related to rate of change and the inclusion of these 
factors as covariates did not materially alter the pattern of results (see Supplemental 
Material).  
There was no evidence that the length of follow-up influenced rate of WMH 
accumulation (p-value > 0.5, all tests).  
 
Figure 3 presents the evolution in WMH for two LMCI subjects with the same WMH 
load at baseline, one with ε33 and the other with ε44. Images are shown at baseline 
and after 2 years. 
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Discussion 
 
This longitudinal study shows a strong association between the APOE status and the 
rate of WMH volume accumulation. We observed an increased rate of change in the 
homozygous 44 compared to the 33 and 43 carriers in a cohort with relatively low 
vascular risk factors and WMH burden at baseline. This study included healthy 
control subjects, people with mild cognitive impairment and individuals with an AD 
diagnosis. These findings were observed independently of diagnosis, and when 
adjusted for CSF Aβ42 levels, although the latter adjustment did modify the effect 
size. 
 
In the ADNI study, exclusion criteria were designed to limit the amount of vascular 
disease using a threshold of 4 on the Hachinski score. Therefore, results obtained 
from this sample may not necessarily generalize to the population at large. For 
instance, the change of 22 % per year observed for the APOE ε4ε4 group might be 
less likely to occur at higher initial lesion loads (with a larger denominator). The bias 
towards a vascular-risk free population may further explain why no statistically 
significant differences at baseline were observed in our sample with respect to APOE 
status. Compared with the general population, this cohort appears enriched in 
subjects carrying APOE ε4 alleles mostly in the MCI group, which may have helped in 
extracting relevant patterns and allowed the distinction between heterozygous ε4ε3 
and homozygous ε4ε4.  Additionally, the differences observed in terms of study 
length for the LMCI and AD groups may have led to an underestimation of the 
observed pattern differences. In the case of the AD population an additional 
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selection bias might be added since subjects accumulating higher loads of WMH and 
AD pathology may drop out more quickly than those with few WMH; in ADs four 
time points may be more difficult to achieve. Despite these potential limitations, a 
tendency for increased WMH volume and rates of change with diagnostic severity 
was still observed.  
 
Ensuring the appropriate modelling of biological processes is not trivial. A variety of 
different ways of modelling change in WMH are used in the literature making 
comparisons difficult across studies. Most studies calculate absolute changes on an 
untransformed scale. However, since there is evidence that WMH changes are 
positively related to baseline WMH volume load in both normal and dementia 
populations (Sachdev, Wen, Chen, & Brodaty, 2007; Schmidt, Enzinger, Ropele, 
Schmidt, & Fazekas, 2003) we chose to analyze changes on a log scale since they 
implicitly allow the magnitude of absolute change to be related to baseline level.  
 
Our finding that different patterns of WMH evolution were related to APOE status is 
consistent with previously reported results (Godin et al., 2009) in normal aging, with 
a much higher rate of increase in subjects homozygous for APOE ε4 compared with 
heterozygous subjects or non-carriers. The observation of no statistically significant 
difference in rate of change between heterozygous 43 and homozygous 33 may be 
taken as a possible explanation for disagreements regarding the link of APOE ε4 and 
WMH evolution since in some studies the population was simply dichotomized into 
carriers and non-carriers (Lo & Jagust, 2012). The different strengths observed with 
the covariates for the 43 and 33 carriers may reflect potential differences in the 
pathological process between these two groups.  
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The association between amyloid pathology, APOE and WMH probably reflects the 
link between Aβ, APOE ε4 and cerebral amyloid angiopathy (CAA)(Haglund & 
Englund, 2002; Verghese et al., 2011). Since a similar tendency was observed after 
adjustment for diagnostic group or Aβ level, the additional effects of APOE on the 
vasculature, independently of amyloid, are likely to account for the much faster 
increase in WMH for subjects homozygous ε4 subjects; though amyloid has an 
independent effect in itself, as indicated by the significant interaction term.  
 
Though the synergetic circle linking WMH, Aβ and amyloid deposition is widely 
documented (Donahue & Johanson, 2008; Gupta, Iadecola, & York, 2015; Verghese et 
al., 2011; Zlokovic, 2011), other explanations for the relationships between APOE 
status and WMH have been suggested. The APOE ε4 allele has been linked with the 
permeability of the blood brain barrier (BBB) and with a decrease in the tight 
junctions of the blood vessels’ endothelium (Nishitsuji, Hosono, Nakamura, Bu, & 
Michikawa, 2011). An increased permeability could in turn lead to 
neuroinflammatory processes, which may contribute to the development of WMH. 
The dose-dependent association with the number of ε4 alleles could be linked to the 
hypothesis of the potential protective effect of allele ε3 on the BBB with respect to 
neuroinflammation (Bell et al., 2012). Furthermore, APOE ε4 has been associated 
with a decrease in glucose uptake, thus leading to deprived regions more vulnerable 
to ischemia (Alata, Ye, St-Amour, Vandal, & Calon, 2014). APOE ε4 homozygotes have 
also been associated with a reduction in capillary surface (Salloway et al., 2002) in 
AD; this reduction would directly affect the blood supply in white matter thereby 
promoting the development of WMH lesions.  The association of APOE ε4 with 
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microbleeds (Yates et al., 2014) could be related to the exacerbated deleterious 
effects of vascular risk factors on WM in APOE ε4 carriers (De Leeuw et al., 2004; 
Wang et al., 2015). The possible joint effects and interaction of vascular risk factors 
such as hypertension and APOE ε4 on the blood vessels is therefore in need of 
further investigation with respect to the development of WMH.  
 
So far, cross-sectional studies have reported contradictory findings regarding the 
relationship between APOE ε4 and WMH. This is further illustrated here by the 
absence of evidence of a difference across genetic status at baseline while 
significantly different rates of change were observed.  This finding strongly supports 
the need to better understand the time course and developmental pattern of 
pathological processes. Cross-sectional studies need to consider age imbalances 
between groups since it is well understood that increasing age has a strong 
association with WMH accrual (van Dijk et al., 2008). In our study, we chose to 
adjust for age as is done in most WMH accrual studies (Godin et al., 2009). This age 
adjustment explains why the AD group have larger WMH volumes  than the 
somewhat younger late MCI group before (table 1), but not after age adjustment 
(table 2). Limitations of cross-sectional studies may be partially overcome by the 
application of longitudinal models.  
 
One of the main strengths of this study is the use of a novel longitudinal method of 
WMH assessment developed for this purpose. The average image on which a 
generative model is built enables the reduction of measurement noise and accounts 
for the within-subject correlation. Accounting for such correlation instead of simply 
applying cross-sectional methods to serial scans for quantitative assessment has 
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been shown to reduce the measurement variability (Reuter, Schmansky, Rosas, & 
Fischl, 2012). Furthermore, the creation of an average image in a mid-space 
overcomes the problem of a bias towards a specific time-point (Fox, Ridgway, & 
Schott, 2011; Reuter & Fischl, 2011).  Lastly, the use of the generative model to 
constrain the segmentation at each time point allows subtle changes to be measured 
while maintaining robustness. 
 
This study has a number of limitations. Due to the complexity of the possible 
biophysiological interactions between amyloid compounds and apolipoprotein, any 
statistical conclusions should be treated cautiously. As such, CSF level of Aβ-42 used 
as a surrogate disease marker for AD pathology (Andreasen et al., 1999) is also 
known to be related to WMH (Stenset et al., 2006). Use of CSF Aβ-40 measures, more 
associated to vascular deposition, may be informative of the pathological process. 
Further work is thus needed to help disentangle WMH progression and CSF Aβ-42 
level changes in the pathogenesis of Alzheimer’s disease. Moreover, only global 
WMH loads were considered here, but regional assessment of the lesion growth and 
differences in pattern across regions could improve our understanding of the 
complex relationship between APOE, AD and vascular pathology. Allele ε2 carriers 
were included in this study and results suggested a protective effect of allele ε2 but 
the very low prevalence of this allele makes investigation difficult. Although a similar 
link between the allele ε2 and WMH has been reported (Gesierich et al., 2015), the 
very limited number of subjects means our results should be considered very 
cautiously. In particular, given the 95% CI found for the 42 group (only 6 subjects), 
the mean negative accrual of WMH cannot be interpreted as significantly different 
from 0. This is mostly representative of the difficulty to represent relative changes 
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for very small measured volumes. Caution in the interpretation is also warranted 
here with respect to the ε4 carriers since only 24 homozygous 44 participants were 
included in the study.  
 
In conclusion, this study shows the impact of APOE ε4 on the rate of WMH accrual 
over and above diagnosis of AD. Carriage of a single ε4 allele with a complementary 
allele ε3 gave a non- significant additional increase of 3% per year, whereas 
homozygous carriers had a significant additional increase of 16% per year compared 
with ε3 homozygotes. APOE ε4, especially when in the homozygous form, is an 
important independent factor in the progression of WMH. 
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Figure 1. Flowchart of the subject selection. Red boxes reflect the number of 
discarded subjects. 
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Figure 2. Flowchart of the longitudinal framework and its three main components. 
The red filled boxes refer to the space of the average image while the blue boxes 
correspond to the set of individual time points images and the green boxes to 
performed actions 
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Table 1: Demographics findings across APOE and diagnostic 
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Table 2 Baseline models: effects of covariates on differences in WMH volumes across 
diagnostic groups and APOE genotypes when adjusting for age, sex and TIV. Results 
are presented back-transformed to their original scale.  
Values are for a standardized 50/50 mixture of males and females at age 72.2 years 
with a TIV of 1552 mL 
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Table 3 Longitudinal models: effect of baseline predictors on differences in WMH 
volume change when adjusting for age, sex and TIV. Standardized percentage 
changes are presented along with the confidence intervals.  Values are standardized 
to a 50/50 mixture of males and females of age 72.2 years with a TIV of 1552 mL 
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Figure 3 Longitudinal segmentation for two LMCI subjects with APOE status 33 (first 
row) and 44 (second row) with same lesion load at baseline. For each subject the 
FLAIR image and the corresponding lesion segmentation (red filled) are presented 
for the baseline (left) and after two years (right). Note the faster rate of 
accumulation for the homozygous APOE ε4 subject (right).  
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    APOE status 
Criterion Diagnosis 32 33 42 43 44 Global 
Number 
 Total  
(Female) 
NC 11 (6) 56 (29) 0 (0) 18 (9) 3 (3) 88 (47) 
EMCI 14 (11) 76 (39) 3 (2) 52 (31) 4 (4) 149 (87) 
LMCI 8 (3) 27 (15) 2 (0) 24 (7) 11 (6) 72 (31) 
AD 0 (0) 9 (6) 1 (1) 14 (9) 6 (5) 30 (21) 
Global 33 (20) 168 (89) 6 (3) 108 (56) 24 (18) 339 (186) 
Age years  
mean (SD) 
NC 73.3 (6.2) 74.2 (5.8) / 73 (8) 78.1 (9.7) 74 (6.4) 
EMCI 68.7 (6.6) 71.6 (7.2) 75.3 (5.7) 69.7 (7.2) 68.4 (5.1) 70.7 (7.1) 
LMCI 78.4 (9.5) 71.4 (7.5) 64.3 (2) 71.4 (8.1) 70.6 (7.2) 71.9 (8.1) 
AD / 78.8 (6) 71.1 (0) 74.6 (7.3) 70.1 (7.2) 74.8 (7.3) 
Global 72.6 (8) 72.8 (7) 71 (6.5) 71.3 (7.7) 71.1 (7.3) 72.2 (7.3) 
TIV mL  
mean (SD) 
NC 1497 (133) 1530 (169) / 1543 (152) 1680 (46) 1534 (160) 
EMCI 1604 (167) 1564 (123) 1537 (81) 1565 (165) 1720 (45) 1572 (143) 
LMCI 1579 (148) 1553 (158) 1435 (92) 1516 (201) 1492 (127) 1531 (167) 
AD / 1568 (178) 1510 (0) 1557 (174) 1537 (131) 1555 (159) 
Global 1562 (155) 1551 (148) 1498 (83) 1549 (171) 1565 (141) 1552 (155) 
Study 
duration 
months  
mean (SD) 
NC 25.8 (3.5) 23.1 (7.4) / 21.9 (4.9) 25.3 (0.6) 23.3 (6.5) 
EMCI 25.1 (11.7) 26.1 (10.4) 28.3 (16.6) 27.4 (12.1) 30.8 (12.2) 26.6 (11.2) 
LMCI 22.8 (5.8) 23.9 (5.6) 25.5 (0.7) 23.4 (8.1) 19.1 (6) 22.9 (6.6) 
AD / 14.6 (4.1) 12 (0) 15.8 (5.9) 20.5 (6.2) 16.2 (5.7) 
Global 24.8 (8.2) 24.1 (8.9) 24.7 (12.3) 24.1 (10.4) 22.2 (7.9) 24 (9.3) 
Aβ ng/mL  
mean [SD;N] 
NC 220 [53; 10] 201 [43; 53] / 173 [42; 15] 111 [42; 3] 194 (48; 81] 
EMCI 216 [42; 10] 198 [47; 73] 115 [0; 1] 170 [48; 50] 121 [14; 3] 187 (50; 137] 
LMCI 193 [43; 8] 196 [45; 26] 129 [51; 2] 138 [33; 23] 114 [31; 11] 162 (51; 70] 
AD / 156 [52; 9] / 143 [41; 14] 102 [10; 6] 139 (45; 29] 
Global 211 [46; 28] 196 [46; 161] 125 [37; 3] 160 [45; 102] 111 [26; 23] 179 (52; 317] 
WMH mL 
 median [IQR] 
NC 0.98 [0.72 1.85] 0.99 [0.54 2.51] / 1.38 [0.84 3.92] 2.07 [1.84 12.65] 1.1 [0.65 2.75] 
EMCI 0.77 [0.33 2.42] 1.23 [0.65 4.79] 0.4 [0.3 12.68] 1.69 [0.36 4.23] 0.9 [0.51 10.30] 1.23 [0.50 4.27] 
LMCI 5.55 [3.26 11.75] 1.7 [0.83 3.95] 1.62 [0.47 2.76] 0.97 [0.50 4.32] 2.18 [1.04 6.22] 1.78 [0.73 5.49] 
AD / 5.56 [1.88 6.30] 1.05 [1.05 1.05] 3.05 [1.33 5.32] 0.61 [0.30 3.05] 2.66 [1.06 5.56] 
Global 1.25 [0.71 3.95] 1.32 [0.67 4.21] 0.76 [0.4 2.76] 1.63 [0.50 4.26] 1.71 [0.75 4.15] 1.36 [0.61 4.25] 
Acronyms expansion: TIV – Total Intracranial Volume; NC – Normal Controls; EMCI – Early Mild Cognitive 
Impairment; LMCI – Late Mild Cognitive Impairment; AD – Alzheimer’s Disease; Aβ - Aβ CSF level; WMH – 
White Matter Hyperintensity; IQR – InterQuartile Range; SD – Standard Deviation; N - Number 
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    APOE Diagnosis 
  
32 33 42 43 44 Normal EMCI LMCI AD 
  Number (Aβ) 33 (28) 168 (161) 6 (3) 108 (102) 24 (23) 88 (81) 149 (137) 72 (70) 30 (29) 
ASTG 
Mean 1.54 1.44 1.42 1.69 2.12 
NA 
CI [1.06 2.23] [1.22 1.70] [0.59 3.40] [1.37 2.07] [1.36 3.29] 
Overall p-
value 
0.5069 
Pairwise / 
ASTD 
Mean 
NA 
1.15 1.67 1.92 1.71 
CI [0.92 1.44] [1.4 2] [1.49 2.46] [1.15 2.52] 
Overall p-
value 
0.0157 
Pairwise EMCI vs Normal *; LMCI vs Normal ** 
ASTGD 
Mean 1.57 1.49 1.28 1.64 1.98 1.17 1.7 1.88 1.64 
CI [1.07 2.3] [1.23 1.80] [0.54 3.04] [1.32 2.03] [1.27 3.08] [0.86 1.59] [1.31 2.21] [1.39 2.52] [1.07 2.52] 
Overall p-
value 
0.7786 0.0331 
Pairwise / EMCI vs Normal *; LMCI vs Normal ** 
ASTGAβ 
Mean 2.09 1.58 1.08 1.50 1.49 
NA 
CI [1.38 3.15] [1.33 1.89] [0.31 3.73] [1.21 1.87] [0.91 2.41] 
Overall p-
value 
0.6996 
Pairwise / 
Model covariates: ASTD – Age Sex TIV Diagnosis; ASTG – Age Sex TIV Genetic status; ASTGD – Age Sex TIV Diagnosis Genetic status; ASTGAβ - 
Age Sex TIV Genetic status Aβ level 
Other acronyms: TIV – Total Intracranial Volume; NA – Not applicable; NC – Normal Control; EMCI – Early Mild Cognitive Impairment; LMCI – 
Late Mild Cognitive Impairment; AD – Alzheimer’s Disease; CI – Confidence Interval 
p-values: * p<0.05; ** p<0.01 
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    APOE Diagnosis 
  
32 33 42 43 44 Normal EMCI LMCI AD 
  Number (Aβ) 33 (28) 168 (161) 6 (3) 108 (102) 24 (23) 88 (81) 149 (137) 72 (70) 30 (29) 
ASTG 
% change/year 2.80 6.64 -3.21 9.98 22.54 
NA 
CI [-2.58 8.47] [4.09 9.26] [-14.76 9.91] [6.66 13.40] [14.43 31.22] 
Overall p-value 0.0002 
Pairwise 32 vs 43 *; 32 vs 44 ***; 33 vs 44 ***; 42 vs 44 **; 43 vs 44 ** 
ASTD 
% change/year 
NA 
5.81 6.57 12.54 14.65 
CI [2.15 9.59] [3.86 9.36] [8.24 17.02] [5.97 24.03] 
Overall p-value 0.0303 
Pairwise EMCI vs LMCI *; Normal vs LMCI * 
ASTGD 
% change/year 3.88 7.96 -3.21 10.76 21.69 5.25 5.92 10.80 9.76 
CI [-1.91 10.01] [4.65 11.36] [-14.82 9.98] [7.00 14.65] [13.63 30.31] [0.56 10.16] [1.99 10.00] [5.96 15.87] [1.09 19.17] 
Overall p-value 0.0016 0.1811 
Pairwise 32 vs 43 *; 32 vs 44 ***; 33 vs 44 **; 42 vs 43 *; 42 vs 44 **; 43 vs 44 * / 
ASTGAβ 
% change/year 6.10 7.21 -10.59 9.16 20.22 
NA 
CI [0.24 12.32] [4.54 9.95] [-24.53 5.92] [5.79 12.63] [11.79 29.28] 
Overall p-value 0.0061 
Pairwise 32 vs 44 *; 33 vs 44 **; 42 vs 43 *; 42 vs 44 **; 43 vs 44 * 
Model covariates: ASTD – Age Sex TIV Diagnosis; ASTG – Age Sex TIV Genetic status; ASTGD – Age Sex TIV Diagnosis Genetic status; ASTGAβ - Age Sex TIV Genetic 
status Aβ level 
Other acronyms: TIV – Total Intracranial Volume; NA – Not applicable; NC – Normal Control; EMCI – Early Mild Cognitive Impairment; LMCI – Late Mild Cognitive 
Impairment; AD – Alzheimer’s Disease; CI – Confidence Interval 
p-values: * p<0.05; ** p<0.01; *** p<0.001 
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Highlights NBA 
 
• Longitudinal automated lesion segmentation applied to ADNI cohort 
• Stronger rate of increase of WMH in homozygous APOE ε4ε4 than other groups 
• APOE ε4 effect on white matter lesion independent of diagnosis 
